Literature DB >> 23912175

Increased soluble Flt-1 correlates with delayed graft function and early loss of peritubular capillaries in the kidney graft.

Marion Chapal1, Mélanie Néel, Florent Le Borgne, Emanuelle Meffray, Odette Carceles, Maryvonne Hourmant, Magalie Giral, Yohann Foucher, Anne Moreau, Fadi Fakhouri.   

Abstract

BACKGROUND: Ischemia-reperfusion induces tubular and endothelial damage in the renal graft and leads to delayed graft function (DGF) and to an early loss of peritubular capillaries (PTC). Few, if any, clinical studies have assessed the impact of proangiogenic and antiangiogenic factors on endothelial repair during renal transplantation (RT)-related ischemia-reperfusion.
METHODS: We prospectively assessed the kinetics of the antiangiogenic factor soluble Fms-like tyrosine kinase-1 (sFlt-1) in 136 consecutive RT patients and analyzed sFlt-1 impact on DGF and PTC loss.
RESULTS: sFlt-1 plasma levels increased by twofold to threefold throughout the first week after RT. This increase was more marked in recipients of grafts from deceased donors compared with living donors. Patients with DGF had higher sFlt-1 levels at all time points during the first 7 days after RT and a higher peak sFlt-1 compared with those without DGF. In multivariate analysis, a peak plasma sFlt-1 of 250 pg/mL or higher was associated with 2.5-fold increase in the risk of DGF (P=0.04). Similarly, patients with a peak plasma sFlt-1 of 250 pg/mL or higher had a more pronounced early decrease in PTC compared with those with a peak sFlt-1 less than 250 pg/mL.
CONCLUSIONS: sFlt-1 is a new nonimmunologic independent risk factor for DGF and PTC loss. Its inhibition may help improve the outcome of RT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912175     DOI: 10.1097/TP.0b013e31829f4772

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  A novel therapy to attenuate acute kidney injury and ischemic allograft damage after allogenic kidney transplantation in mice.

Authors:  Faikah Gueler; Nelli Shushakova; Michael Mengel; Katja Hueper; Rongjun Chen; Xiaokun Liu; Joon-Keun Park; Hermann Haller; Gert Wensvoort; Song Rong
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

2.  Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD.

Authors:  Zsuzsanna K Zsengellér; Agnes Lo; Mahtab Tavasoli; Elizabeth Pernicone; S Ananth Karumanchi; Seymour Rosen
Journal:  Kidney Int Rep       Date:  2019-08-14

3.  The VEGF Inhibitor Soluble Fms-like Tyrosine Kinase 1 Does Not Promote AKI-to-CKD Transition.

Authors:  Cleo C L van Aanhold; Angela Koudijs; Kyra L Dijkstra; Ron Wolterbeek; Jan A Bruijn; Cees van Kooten; Hans J Baelde
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

Review 4.  Circulating Soluble Fms-like Tyrosine Kinase in Renal Diseases Other than Preeclampsia.

Authors:  Theresa M Wewers; Annika Schulz; Ingo Nolte; Hermann Pavenstädt; Marcus Brand; Giovana S Di Marco
Journal:  J Am Soc Nephrol       Date:  2021-06-21       Impact factor: 14.978

Review 5.  The Role of Krüppel-like Factor 4 in Renal Fibrosis.

Authors:  Ben Ke; Afei Zhang; Xianfeng Wu; Xiangdong Fang
Journal:  Front Physiol       Date:  2015-11-12       Impact factor: 4.566

Review 6.  Endogenous Antiangiogenic Factors in Chronic Kidney Disease: Potential Biomarkers of Progression.

Authors:  Katsuyuki Tanabe; Yasufumi Sato; Jun Wada
Journal:  Int J Mol Sci       Date:  2018-06-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.